CAS 1051375-16-6

Dolutegravir

Descripción:

Dolutegravir es un medicamento antirretroviral que se utiliza principalmente en el tratamiento de la infección por VIH. Pertenece a la clase de fármacos conocidos como inhibidores de la transferencia de cadena de integrasa (INSTIs), que actúan bloqueando la enzima integrasa, impidiendo la integración del ADN viral en el genoma de la célula huésped. Dolutegravir se caracteriza por su alta potencia, perfil farmacocinético favorable y una baja barrera a la resistencia, lo que lo hace efectivo en varios regímenes de tratamiento. La sustancia se administra típicamente por vía oral y se absorbe bien, con una larga vida media que permite una dosificación una vez al día. A menudo se combina con otros agentes antirretrovirales para mejorar la eficacia y reducir el riesgo de resistencia. Dolutegravir generalmente es bien tolerado, aunque algunos pacientes pueden experimentar efectos secundarios como insomnio, dolor de cabeza o trastornos gastrointestinales. Su estructura química incluye un núcleo bicíclico, lo que contribuye a su mecanismo de acción y estabilidad. En general, Dolutegravir representa un avance significativo en la terapia del VIH, mejorando los resultados del tratamiento para muchos pacientes.

Fórmula: C₂₀H₁₉F₂N₃O₅

InChI: InChI=1S/C20H19F2N3O5/c1-10-4-5-30-15-9-24-8-13(17(26)18(27)16(24)20(29)25(10)15)19(28)23-7-11-2-3-12(21)6-14(11)22/h2-3,6,8,10,15,27H,4-5,7,9H2,1H3,(H,23,28)/t10-,15+/m1/s1

Clave InChI: InChIKey=RHWKPHLQXYSBKR-BMIGLBTASA-N

SMILES: O=C1C=2N(C[C@]3(N1[C@H](C)CCO3)[H])C=C(C(NCC4=C(F)C=C(F)C=C4)=O)C(=O)C2O

Sinónimos:

• (4R,12aS)-N-[(2,4-Difluorophenyl)methyl]-3,4,6,8,12,12a-hexahydro-7-hydroxy-4-methyl-6,8-dioxo-2H-pyrido[1',2':4,5]pyrazino[2,1-b][1,3]oxazine-9-carboxamide
• (4R,12aS)-N-[(2,4-Difluorophenyl)methyl]-3,4,6,8,12,12a-hexahydro-7-hydroxy-4-methyl-6,8-dioxo-2H-pyrido[1′,2′:4,5]pyrazino[2,1-b][1,3]oxazine-9-carboxamide
• (4R,9aS)-5-Hydroxy-4-methyl-6,10-dioxo-3,4,6,9,9a,10-hexahydro-2H-1-oxa-4a,8a-diaza-anthracene-7-carboxylic acid 2,4-difluoro-benylamide
• 2H-Pyrido[1′,2′:4,5]pyrazino[2,1-b][1,3]oxazine-9-carboxamide, N-[(2,4-difluorophenyl)methyl]-3,4,6,8,12,12a-hexahydro-7-hydroxy-4-methyl-6,8-dioxo-, (4R,12aS)-
• Dolutegravir free acid
• Gsk 1349572
• Gsk1349572
• S/Gsk1349572
• Soltegravir
• Tivicay
• Dolutegravir

Dolutegravir

CAS: 1051375-16-6

Dolutegravir

Pureza: ≥98%

Peso molecular: 419.38g/mol

Ref: 54-BUP15005

(4R,12aS)-N-(2,4-Difluorobenzyl)-7-Hydroxy-4-Methyl-6,8-Dioxo-3,4,6,8,12,12a-Hexahydro-2H-Pyrido[1',2':4,5]Pyrazino[2,1-b][1,3]Oxazine-9-Carboxamide

CAS: 1051375-16-6

(4R,12aS)-N-(2,4-Difluorobenzyl)-7-Hydroxy-4-Methyl-6,8-Dioxo-3,4,6,8,12,12a-Hexahydro-2H-Pyrido[1',2':4,5]Pyrazino[2,1-b][1,3]Oxazine-9-Carboxamide

Pureza: 98%

Peso molecular: 419.38g/mol

Ref: 54-PC109099

Dolutegravir

CAS: 1051375-16-6

Fórmula: C₂₀H₁₉F₂N₃O₅

Forma y color: White To Off-White Solid

Peso molecular: 419.38

Ref: 4Z-D-093001

Dolutegravir-d5

CAS: 1051375-16-6

Fórmula: C₂₀H₁₄D₅F₂N₃O₅

Forma y color: Off-White Solid

Peso molecular: 424.42

Ref: 4Z-D-093002

Dolutegravir

CAS: 1051375-16-6

Dolutegravir (GSK1349572), HIV integrase inhibitor with IC50 of 2.7 nM, partly effective against some raltegravir-resistant HIV strains.

Fórmula: C₂₀H₁₉F₂N₃O₅

Pureza: 98.97% - 99.75%

Forma y color: White To Pale Yellow Solid

Peso molecular: 419.38

Ref: TM-T6198

Dolutegravir-d6

CAS: 1051375-16-6

Fórmula: C₂₀H₁₃D₆F₂N₃O₅

Peso molecular: 425.42

Ref: 4Z-D-093045

Dolutegravir (0.1 mg/mL in Methanol)

CAS: 1051375-16-6

Fórmula: C₂₀H₁₉F₂N₃O₅

Forma y color: Colourless

Peso molecular: 419.38

Ref: TR-KIT7755

Dolutegravir

CAS: 1051375-16-6

Applications Dolutegravir is a second generation HIV-1 integrase strand transfer inhibitor. Dolutegravir is currently in Phase III clinical trials for the treatment of HIV infection. Dolutegravir has been shown to potently inhibit HIV replication in cells such as peripheral blood mononuclear cells (PBMCs), MT-4 cells and CIP4 cells infected with a self-inactivating PHIV lentiviral vector.
References Kobayashi, M. et al. Antimicrob Agents Chemother., 55, 813 (2011); Garrido, C. et al.: Antiviral, Res., 90, 164 (2011); Lenz, J.C.C. et al.: Exp. Opin. Invest. Drugs, 20, 537 (2011);

Fórmula: C₂₀H₁₉F₂N₃O₅

Forma y color: White To Beige

Peso molecular: 419.38

Ref: TR-D528800

Dolutegravir-d4

Producto controlado

CAS: 1051375-16-6

Applications Isotope labelled Dolutegravir is a second generation HIV-1 integrase strand transfer inhibitor. Dolutegravir is currently in Phase III clinical trials for the treatment of HIV infection. Dolutegravir has been shown to potently inhibit HIV replication in cells such as peripheral blood mononuclear cells (PBMCs), MT-4 cells and CIP4 cells infected with a self-inactivating PHIV lentiviral vector.
References Kobayashi, M. et al. Antimicrob Agents Chemother., 55, 813 (2011); Garrido, C. et al.: Antiviral, Res., 90, 164 (2011); Lenz, J.C.C. et al.: Exp. Opin. Invest. Drugs, 20, 537 (2011);

Fórmula: C₂₀H₁₅D₄F₂N₃O₅

Pureza: >80%

Forma y color: Neat

Peso molecular: 423.40

Ref: TR-D528802

Dolutegravir

CAS: 1051375-16-6

Dolutegravir is an HIV-1 integrase inhibitor. Dolutegravir is used in the treatment of HIV-1 infections as it hampers the integration of the viral genome into the host DNA (Katlama, 2012). Active on a wide number of HIV-1 phenotypes, dolutegravir is highly bioavailable with an IC90 of more than 30 hours (Cottrell, 2013).

Fórmula: C₂₀H₁₉F₂N₃O₅

Pureza: Min. 98 Area-%

Forma y color: White Powder

Peso molecular: 419.40 g/mol

Ref: 3D-FD43372

Dolutegravir

CAS: 1051375-16-6

Pureza: 98%

Peso molecular: 419.385

Ref: 10-F799806